0000950170-24-016803.txt : 20240220 0000950170-24-016803.hdr.sgml : 20240220 20240220074223 ACCESSION NUMBER: 0000950170-24-016803 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Francis Richard D CENTRAL INDEX KEY: 0001673277 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 24650748 MAIL ADDRESS: STREET 1: IM LANGACHER 44 CITY: GREIFENSEE STATE: V8 ZIP: 8606 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 BUSINESS PHONE: 972 (3) 914-8213 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 4 1 ownership.xml 4 X0508 4 2024-02-15 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001673277 Francis Richard D C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL false true false false President and CEO true Ordinary Shares 2024-02-15 4 M false 161655 A 161655 D Ordinary Shares 2024-02-15 4 S false 74530 13.1514 D 87125 D Restricted Share Units 2024-02-15 4 M false 161655 0 D Ordinary Shares 161655 323311 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.09 to $13.24, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026. /s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis 2024-02-20